Therapeutics News and Research

RSS

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.

7 Oct 2015

Recipients of 2015 Ferring Innovation Grants announced

Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. This global program awards each recipient $50,000 to support research in the fields of Reproductive Health, Gastroenterology and/or Urology.

7 Oct 2015

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes.

7 Oct 2015

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

Rhythmic expression of key genes is essential for maintaining proper timekeeping of the body's clock. In addition, rhythmic degradation of clockwork proteins is also crucial. However, surprisingly, researchers know little about these specific processes.

7 Oct 2015

First patients screened in Axovant's phase 3 study of RVT-101

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.

6 Oct 2015

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).

6 Oct 2015

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

6 Oct 2015

Novel computational strategy may help identify genetic variants that cause disease in children

The team behind the Deciphering Developmental Disorders (DDD) Study, one of the world's largest nationwide rare disease genome-wide sequencing initiatives, have developed a novel computational approach to identify genetic variants that cause disease in young children.

6 Oct 2015

First-time expectant dads experience depression

Transition to parenthood can be a difficult life event. It can have an impact on both parents and on the long-term development of the child. While mother's "baby blues" have been widely investigated, little research has been conducted on antenatal paternal depression. A team from the Research Institute of the McGill University Health Centre sheds light on fathers' mental health by releasing the first study to report the prevalence of antenatal depression symptoms among Canadian men.

6 Oct 2015

Researchers identify role of microglia during early stages of Alzheimer's disease

For the first time, researchers have determined how toxic tau fibrils spread by the help of brain immune cells called microglia during the early stages of Alzheimer's disease (AD). The discovery of this new pathway may lead to a therapeutic target for AD, one that has not been previously identified.

5 Oct 2015

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

PTC Therapeutics, Inc., today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K.

5 Oct 2015

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market.

1 Oct 2015

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

The results show that Oraya Therapy is effective in maintaining vision with reduced injections for patients at different stages of their disease—from chronic patients in discontinuous treatment to treatment-naive patients with new diagnosis—and following different treatment pathways.

1 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Tunitas Therapeutics completes $10 million Series A venture financing

Tunitas Therapeutics, Inc. today announced the close of a $10 million Series A venture financing. The financing was co-led by Ally Bridge Group and WuXi Ventures, with the further participation of RA Capital Advisors.

30 Sep 2015

New review article discusses benefits, limitations of current screening mammography practices

While screening mammography has a well-established history of reducing death from breast cancer and enabling earlier detection of breast disease, questions regarding overtreatment and overdiagnosis have entered the screening debate.

30 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Unique molecule can bind HIV-infected cells to killer T cells

A unique molecule developed at Duke Medicine, the University of North Carolina at Chapel Hill and MacroGenics, Inc., is able to bind HIV-infected cells to the immune system's killer T cells. It could become a key part of a shock-and-kill strategy being developed in the hope of one day clearing HIV infection.

29 Sep 2015

Therapeutics News and Research

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

Recipients of 2015 Ferring Innovation Grants announced

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

First patients screened in Axovant's phase 3 study of RVT-101

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Novel computational strategy may help identify genetic variants that cause disease in children

First-time expectant dads experience depression

Researchers identify role of microglia during early stages of Alzheimer's disease

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Tunitas Therapeutics completes $10 million Series A venture financing

New review article discusses benefits, limitations of current screening mammography practices

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Unique molecule can bind HIV-infected cells to killer T cells

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News